Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.

Abstract

The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea. The study randomized 231 patients with poorly controlled (HbA_1c >7.5%, 58 mmol/mol) T2DM on a sulfonylurea plus metformin to receive <i>1</i>) pioglitazone plus weekly exenatide (combination therapy) or <i>2</i>) basal plus prandial insulin (insulin therapy) to maintain HbA_1c <7.0% (53 mmol/mol). After a mean follow-up of 12 months, combination therapy caused a robust decrease in HbA_1c from 10.0 ± 0.6% (86 ± 5.2 mmol/mol) at baseline to 6.1 ± 0.1% (43 ± 0.7 mmol/mol) compared with 7.1 ± 0.1% (54 ± 0.8 mmol/mol) in subjects receiving insulin therapy. Combination therapy was effective in lowering the HbA_1c independent of sex, ethnicity, BMI, or baseline HbA_1c. Subjects in the insulin therapy group experienced significantly greater weight gain and a threefold higher rate of hypoglycemia than patients in the combination therapy group. Combination exenatide/pioglitazone therapy is a very effective and safe therapeutic option in patients with long-standing poorly controlled T2DM on metformin plus a sulfonylurea.